Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Excitement At VistaGen Therapeutics (VSTA) Continues To Build 0 comments
    Dec 19, 2012 6:11 PM | about stocks: VSTA

    A lot of great things have been happening with VistaGen Therapeutics recently. VistaGen is a California-based biotechnology company actively applying its proprietary human pluripotent stem cell technology to launch a new era of drug rescue, predictive heart and liver toxicology, and drug metabolism screening.

    VistaGen's unique stem cell technology-based Human Clinical Trials in a Test Tube™ platform currently involves controlled differentiation (development) of pluripotent stem cells into mature, functional human heart and liver cells that can then be used to predict early in development whether a drug candidate has potential toxicity problems. Determination of potential heart and liver toxicity early on in the development process, far earlier than standard tests, means that drug candidates have a chance of being modified for a successful outcome long before resources are expended on costly and time-consuming animal and human clinical studies. Many otherwise promising drug candidates have been shelved due to heart or liver toxicity issues that surfaced well into the development process and even after FDA approval, representing major losses for drug companies.

    By generating new chemical variants of small molecule drug candidates that have shown promise, but are currently on hold due to heart or liver toxicity issues, VistaGen can effectively rescue substantial prior investment by others in discovery and development of the once-promising drugs, building an exclusive and valuable portfolio of proprietary rejuvenated drug candidates. VistaGen plans to have economic participation rights to all of the drug rescue variants it develops, benefitting its bottom line as well as its shareholders. The tremendous promise of this approach has prompted the company's CEO, Shawn Singh, to purchase 100,000 additional common stock shares of the company, bringing his total holdings to 252,174 shares.

    Other recent developments include the company's formalized membership in the Toronto-based Centre for Commercialization of Regenerative Medicine's (CCRM) Industry Consortium. VistaGen aims to expand the commercial applications of their Human Clinical Trials in a Test Tube™ platform by building multi-party collaborations with CCRM and members of its Industry Consortium around drug rescue and regenerative medicine opportunities, including pilot nonclinical programs involving blood, heart, liver, and potentially pancreatic beta islet cells. Speaking of these opportunities, Shawn Singh emphasized that such collaborations have the potential to "transform medicine and accelerate significant advances in human health and wellness that stem cell technologies and regenerative medicine promise."

    In addition, the company had earlier announced the completion of a $3.25 million financing commitment from its largest institutional investor, Platinum Long Term Growth VII, LLC.

    For additional information on VistaGen's stem cell technology and current initiatives, visit VistaGen.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: VSTA
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.